Why Is INTELLIA THERAPEUTIC (NTLA) Stock Down Today?

Intellia Therapeutics (NTLA) shares fell 8.06% to $9.70, driven by a reaction to new clinical data for its lead candidate, lonvo-z. The stock opened higher but reversed sharply during the session as investors processed the latest results from the HAELO Phase 3 trial.

What Happened

Intellia presented additional positive clinical and patient-reported data for lonvoguran ziclumeran at the ACAAI 2026 conference. Among patients previously on long-term prophylaxis in the HAELO Phase 3 trial, the monthly attack rate decreased by 81% following lonvo-z dosing compared with prior prophylaxis. The company noted that 100% of patients receiving the treatment were free of long-term prophylaxis at the latest follow-up.

The firm also reported that 89% of patients experienced an overall attack rate reduction across up to four years after a one-time dose. Intellia reiterated its PDUFA date of March 10, 2027, and stated that the HAELO trial met key secondary quality-of-life endpoints with no serious adverse events in the lonvo-z arm. A Form 8-K was filed on November 12, 2026, disclosing results of operations and financial condition.

What The Data Shows

The stock opened at $10.79, a 2.3% gap up from the prior close of $10.55. It hit a session high of $10.79 at 7:00 AM ET before sliding to a session low of $9.65 at 4:00 PM ET. Volume reached 10.1 million shares, which is 2.3 times the three-month daily average.

Intellia has a market capitalization of $1.6 billion and remains unprofitable with trailing twelve-month earnings per share of negative $3.35. Revenue declined 8.1% over the same period. The stock has a beta of 1.82 and trades within a 52-week range of $7.95 to $18.48. Over the last eight sessions, the stock moved down 11.0% from $11.86 to $10.55. Recent insider activity includes three sales totaling $418,000 in the last 90 days, with no buys recorded.

What To Watch

Investors will monitor the commercial launch preparations for lonvo-z and the upcoming PDUFA decision scheduled for March 10, 2027. The company’s ability to convert clinical data into commercial success will be a key focus for analysts and shareholders in the coming months.